The three rapid-acting insulins currently approved by the US Food and Drug Administration — lispro, aspart (NovoLog), and glulisine (Apidra ) — have similar action curves, with an onset occurring in 5–15 minutes, a peak in 45– 90 minutes, and an overall duration of about 3–4 hours.